Argenx (ARGX)
(Real Time Quote from BATS)
$378.80 USD
+2.99 (0.80%)
Updated Jun 10, 2024 03:50 PM ET
After-Market: $379.34 +0.54 (0.14%) 4:06 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
argenex SE [ARGX]
Reports for Purchase
Showing records 161 - 180 ( 280 total )
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Sticking to CIDP with Efgart in ADHERE Study
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
argenx 2021 Update: Efgartigimod BLA Submitted and SC Bridging Study Underway; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Purchases Priority Review Voucher Likely in Response to Stiffening Competitive Landscape in MG; Reit Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Key Catalysts Expected in Next Six Months as Clinical Trials Progress; Reiterate Neutral, Nudge PT Down to $265
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
3Q20; Efgartigimod BLA Filing and SubQ FDA Meeting by Year End
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Additional ADAPT Data Provides Clarity on Efgartigimod Efficacy in gMG; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Gearing-up for a First-in-Class BLA Submission While Pushing Its Pipeline; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
2Q20 Earnings; Some Cusatuzumab Setbacks, but Efgartigimod Story Intact
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
A Headstart, But the Race Has a Long Way to Go; Initiate at Neutral With a $272 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D